Dig Liver Dis. 2022 Oct;54(10):1320-1327. doi: 10.1016/j.dld.2022.04.028.Epub 2022 May 31.

A Diamanti ¹, A Lezo ², L D'Antiga ³, P Gandullia ⁴, M I Spagnuolo ⁵, P Roggero ⁶, T Capriati ⁷, P Lionetti ⁸

Author information

¹Gastroenterology and Nutritional Rehabilitation Unit, Bambino Gesù Children's Hospital, Piazza Sant'Onofrio 4, Rome, Italy. Electronic address: Antonella.diamanti@opbg.net.

²Dietetics and Clinical Nutrition Unit, Children's Hospital Regina Margherita, Città della Salute e della Scienza Torino, Piazza Polonia 94, Turin, Italy.

³Paediatric Hepatology, Gastroenterology and Transplantation, Hospital Papa Giovanni XXIII, Piazza OMS 1, Bergamo, Italy.

⁴Pediatric Gastroenterology and Endoscopy, IRCCS G.Gaslini Institute, via Gerolamo Gaslini 5, Genoa, Italy.

⁵Department of Translational Medical Sciences, University "Federico II" of Naples, Corso Umberto I 40, Naples, Italy.

⁶Neonatal Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.

⁷Gastroenterology and Nutritional Rehabilitation Unit, Bambino Gesù Children's Hospital, Rome, Italy.

⁸Department NEUROFARBA. University of Florence. Meyer Children's Hospital, viale Gaetano Pieraccini 24, Florence, Italy.

Abstract

In recent years, the spectrum of possible treatments for Intestinal Failure (IF)-Short Bowel Syndrome (SBS) has been enriched by the implementation of GLP-2 analogues. In Italy, teduglutide (Ted), an analogue of GLP-2, was approved in January 2021 by the Italian Regulatory Agency for Drugs (AIFA) for IF-SBS patients ≥1 year old. According to the Agency indications, Ted can now be prescribed by regional reference centers, with costs fully charged to the National Health Service. Following pediatric-use approval in our country and in light of scarce evidence in childhood, the pediatric network for IF of the Italian Society for Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP) planned to share management methods of Ted in pediatric IF. The main purpose was to identify the best candidates from a cost-effective perspective. Thus, focusing on available literature and on expert opinions, the present position statement provides consensus-based recommendations on the use of Ted for pediatric gastroenterologists and nutritionists treating children with SBS.